The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Michelle Lim Gilson - Canaccord Genuity Corp., Research Division - Analyst
: Congratulations on the data. I know it's not apples-to-apples because of the duration of treatment and the baseline. But perhaps you can expand
a little bit on some of your comments about this being the first trial to show a difference in quality of life for SF-36 results in a randomized
placebo-controlled study. And maybe specifically, you can understand -- you can help us understand if there's a comparison to be made with the
results from the REPLACE study, which showed that net par treatment did not result in a statistically significant improvement in either of those
[domains] compared to placebo?
Question: Michelle Lim Gilson - Canaccord Genuity Corp., Research Division - Analyst
: Great. And just as a follow-up, are you planning to report the PRO with your 6-month data later this quarter? And just moving forward, when we
do get those data without a placebo arm in the open-label extension study, how should we think about interpreting the PRO or SF-36 results?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
AUGUST 27, 2020 / 8:30PM, ASND.OQ - Q2 2020 Ascendis Pharma A/S Earnings Call
Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst
: On -- in PTH data today, I'm curious if the 4-week SF-36 results or the HPES results track with the biomarker and supplement withdrawal components
of the primary and key secondary efficacy endpoints in PaTH Forward. Essentially, were the responders on the primary and secondary more likely
to benefit on SF-36 or HPES than the nonresponders? And related to that, it sounds like you're saying that some patients benefited meaningfully
on quality of life, even if they did not meet the responder criteria for some reason. And if so, I was hoping that we could dig into which element of
the responder criteria seemed less important for quality of life. You alluded to calcium in response to an earlier question. Was that serum calcium
or urinary calcium?
Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst
: Okay. And following up on that. Do you see any possibility of changing the planned Phase III endpoint to SF-36 or HPES?
Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst
: Okay. Great. And last one, maybe a quick one. Is it possible to refine when, in the third quarter, we can expect the 6-month PaTH Forward update?
| 
